STUDY TITLE: Open-label Phase 2 Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment

NCT06617858

This is a Phase 2 trial to study the efficacy of AMB-05X in patients with CRC MRD as determined by a ctDNA(+) blood test and no clinically detectable radiographic disease.

Status: Active, Recruiting

 

Key Eligibility Criteria

  • Diagnosis of any stage (I-IV) colorectal adenocarcinoma
  • Completion of all curative-intent treatments
  • No evidence of measurable disease on imaging or clinically detectable disease at least 28 days after completion of all treatment
  • Positive ctDNA test result (Signatera) at least 28 days after completion of all treatment

Treatment

Drug: AMB-05X, anti-CSF1R monoclonal antibody

Study Plan

This is a single group assignment in which participants will be treated every two weeks for six months, followed by surveillance for an average of one year.